Bloomberg | Quint is a multiplatform, Indian business and financial news company. In fact the profit (around 300 cr) Gland pharma made in the entire Year of 2007 was covered in just 1 quarter of FY21 (ie. Photographer: Andrey Rudakov/Bloomberg. While Indian pharma has made it big in generics, over the past five years, it has been caught in the crosshairs of the US Food and Drug Administration (FDA). ... Net profit was up 71% to Rs 313.59 crore. Not surprising that Gland’s R&D cost as percentage of sales is low at 3.5%. If you had invested Rs. Compare. Gland Pharma Ltd. (GPL) is one of the fastest-growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report). View Sample Report Net … Get Gland Pharma detailed stock quotes and technical charts for Gland. … %, -19.5 Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and information in the form of graphs, charts, expert advice, and … Growing Profit Margin: 543245's current net profit margins (31.8%) are higher than last year (24.3%). During the reporting period, totally 15 generic drug products were approved by the US FDA for sales in the market. In 2014, KKR had invested about $200 million to buy a stake of around 38% in Gland Pharma. Strong portfolio of diverse complex injectables. With Shanghai-based Fosun Pharma holding 74 per cent in Gland Pharma before this IPO offer, it is the first company in India to be listed with a Chinese promoter. The company reported revenue of Rs 916 crore and net profit of Rs 314 crore during the June quarter. Gland Pharma Ltd was incorporated as Gland Pharma Private Limited', a private limited company under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad. Watch out! It's EBITDA has increased by 35.62 % over the previous year. Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. Favipiravir, the antiviral medication being manufactured in Russia. The PE firm exited its investment in Gland Pharma with 2.8 times returns by selling its stake to Fosun, according to VCCircle estimates. Pharmaceuticals & Drugs, ₹  It has been reported that the company has received bids for 26.93 lakh equity shares against the IPO size of 3.02 crore equity shares. Actual numbers and more financial data, updated until 31 March, 2019* are included in purchased financial report. Get the latest Gland pharma ltd stock/share markets, Financial Summary with profit/loss, cash folw, balance sheet & the historic stock/share data for Nifty/Sensex today. In the past five fiscals, the company’s net sales have grown at a CAGR of 18.2% to ₹2,633 crore and net profit by 25% to ₹773 crore. The issue opened for bidding on 9 November 2020 and it closed on 11 November 2020. Hyderabad-based Gland Pharma has received the ... Their profit after tax (PAT) increased by 71.02% to Rs 772.95 crores in FY20. Net Profit Margin (%) 29.35. Its revenues grew 21 per cent YoY to Rs 1,749 crore. through issuing fresh equity share, the number of the equity share that will be issued by Gland Pharma is not yet declared but in IPO, company is to sell 34,863,635 Equity Shares. Established in 1978, Gland Pharma is an injectable-focused drugmaker with a footprint across 60 countries, including markets such as the U.S., Europe, Canada, Australia and India. 618.9144, ₹  The current status of Gland Pharma Ltd is - Active. Shares of Gland Pharma Ltd. soared on its market debut as investors piled in expecting to gain from the demand for its injectables. Gland Pharma Share Price - Buy or Invest Gland Pharma with India’s Leading Brokerage Platform with Groww.in. During FY18-20, Gland Pharma’s revenues have grown at a CAGR of 28 per cent while June quarter revenue rose 31 per cent. It will include Gland Pharma Today Share Price, Charts description, Historical Performance, Financial Statements & more. The IPO is worth Rs 6,480 crore. Now if we Check Gland Pharma’s Revenue and Net profit in the year 2017 & 2020 compare, it has grown by many times. The IPO of Gland Pharma was subscribed 2.06 times. Last Bonus. The price band for … About the Company – Gland Pharma Incorporated in 1978, Gland Pharma is one of the largest and fastest-growing injectable-focused companies in the United States of America from 2014-2019. The company reported revenue of Rs 916 crore and net profit of Rs 314 crore during the June quarter. The company has a portfolio of injectable products across various therapeutic areas and delivery systems. Kotak Mahindra Capital Co. Ltd., Citigroup Global Markets India Pvt., Haitong Securities India Pvt. In the June quarter its revenues grew by 31%. Gland Pharma Ltd's operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2019. It entered the US market in 2007. Net profit in financial year 2020 was Rs 772 crore… Ipca Laboratories Ltd. 2,209.15. Find market predictions, GLAND financials and market news. (-0.89%). Subscription of retail investors was 24%. The U.S. is Gland Pharma’s largest market contributing more than 60% to its sales. Company net worth has increased by more than 1.5 times in the last two years. The IPO opens on Nov 9, 2020, and closes on Nov 11, 2020.. Link Intime India Private Ltd is the registrar for the IPO. The initial public offer (IPO) of Gland Pharma received bids for 6.21 crore shares on Wednesday, 11 November 2020, as against 3.02 crore shares on offer. Get MoneyWiz on your webpage. The unique thing about Gland Pharma is that it is a B2B player in the complex injectable space with a profit-sharing model that protects it from market volatility. Add to portfolio. Gland Pharma Share Price will help you analyze todays & historical price of the Brand. Gland Pharma Share Price - Buy or Invest Gland Pharma with India’s Leading Brokerage Platform with Groww.in. In 2014, KKR had invested about $200 million to buy a stake of around 38% in Gland Pharma. Shares of Gland Pharma were trading at Rs 1802.80 at 10:10 IST on the BSE, a premium of 20.19percent over the initial public offer price of Rs 1500. ... Their profit after tax (PAT) increased by 71.02% to Rs 772.95 crores in FY20. The company has a cash-efficient business model with a 30% return on capital employed with operating profit (Ebitda) margin of 41% (among the best in the Indian pharma industry). (212) 419-8286. hadley.ward@statista.com. Cipla: The leading multinational pharmaceutical company Cipla has reported a 41% year-on-year rise in consolidated profit at Rs 665 crore for the quarter ended September 30, 2020. Hyderabad-based Gland Pharma is set to launch its maiden initial public offer on November 9 to raise about Rs 6,500 crore. BloombergQuint. Get detailed Gland Pharma stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. For financial year 2020, revenue stood at Rs 2,772 crore and net profit at Rs 773 crore. NSE: GLAND We combine Bloomberg’s global leadership in business and financial news and data, with Quintillion Media’s deep expertise in the Indian market and digital news delivery, to provide high quality business news, insights and trends for India’s sophisticated audiences. %, 30.6819754193948 The stock is considerably attractive based on intrinsic value. Net profit more than doubled to Rs 772.8 crore from Rs 321 crore during this period, the draft IPO prospectus shows. Gland Pharma Ltd was incorporated as `Gland Pharma Private Limited' a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. LTD & SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Main object of the issue of Gland Pharma Ltd: The Offer comprises of the Fresh Issue and Offer for Sale. About the Company – Gland Pharma Incorporated in 1978, Gland Pharma is one of the largest and fastest-growing injectable-focused companies in the United States of America from 2014-2019. About Gland Pharma Limited IPO. It manufactures a diversified range of high-quality complex injectables. Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. The promoters of Gland Pharma Ltd: FOSUN PHARMA INDUSTRIAL PTE. The stock closed at Rs 1,820, gaining 21.36% over the issue price. With no debt and a large cashpile, the company has strong net profit margins at 29.4 per cent in FY20, which improved from 19.8 per cent in FY18. It is among the fastest-growing generic injectables-focused companies in the country. Ahead of the opening of the IPO, Gland Pharma on Saturday said it has raised a total of Rs 1,944 crore from anchor investors.  SECTOR: It offers injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions. Join our. The company knows very well the utilization of its assets. The issue is priced at ₹1490 to ₹1500 per equity share. That apart, Gland has another edge in high quality control. Gland Pharma IPO - Open & Listing Date, Price, News, DRHP, RHP , Subscription, Allotment and GMP. Through the IPO, the company plans to raise close to Rs 6,500 crore, which is the largest IPO in the pharma sector. Best in class. ADVANTAGES. Gland Pharma Ltd. (GPL) is one of the fastest-growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report). Revenues rose 29% to Rs 2633.24 crore and net profit rose 71% to Rs 772.86 crore in year ended March 2020.Revenues rose31% to Rs 884.21 crore in Q1FY21. The offer comprised a fresh issue of equity shares worth Rs 1,250 crore, and a sale of 3.5 crore shares by promoters and other investors. 1,250 crores and an offer for sale (OFS) of 3.4 crore equity shares by the promoters and other selling shareholders. The company plans capex with the IPO and cash on books, which can temporarily affect the return rations in near term. were lead managers to the issue. Gland Pharma was founded in 1978 to manufacture and market Heparin injection for the domestic market. Best in class. Get Live Gland Pharma stock market chart. Join the Gland Pharma discussion here. Gland Pharma IPO GMP Today, Gland Pharma IPO Grey Market Premium Updates | Gland Pharma IPO Listing Gain, Latest target, Opening gain. For financial year 2020, revenue stood at Rs 2,772 crore and net profit at Rs 773 crore. As of 31 December 2017, Fosun Pharma owned Sisram Medical 52.83% shares. It will also be the Indian company, with Chinese parentage, to tap the primary marker for funding. Gland Pharma sees robust cash flows from operations. Financially, Gland Pharma has reported healthy growth in annual profits. Gland Pharma is launching a Rs. ... As for the net profit earned by the company, that has recorded a CAGR of almost 17% in the period from 2017 to 2020. Highly Speculative. The U.S. is Gland Pharma’s largest market contributing more than 60% to its sales. GLAND - Gland Pharma Share Price ₹2184.75 -6.3 -0.3% Last Trade - 10:25am. The company has already allocated 1.30 crore equity shares at Rs 1,500 apiece to 70 anchor investors, raising Rs 1,944 crore ahead of the IPO. Particularly, the core enterprise Gland Pharma's net profit increased by 52.2% year-on year during the Reporting Period. The company is managed by Fosun Pharma Industrial Private. The IPO is broken down into a fresh issue of 83 lakh shares amounting to Rs. Check Gland Pharma share price, financial data and complete stock analysis.Get Gland Pharma stock rating based on quaterly result, profit and loss account, balance sheet, shareholding pattern and annual report. Get todays Live Stock Price for Gland Pharma with Performance, Fundamentals, Market Cap, Share holding, financial report, company profile, annual report, quarterly results, profit and loss, and more. At the end of financial year 2020, Gland Pharma’s net profit stood at Rs 772.8 … The issue opened for bidding on 9 November 2020 and it closed on 11 November 2020. Check out why Gland Pharma share price is falling today. View live GLAND PHARMA LTD chart to track its stock's price action. the 313 cr in June quarter). Stock price may face volatility due to ownership structure. Net profit in financial year 2020 was Rs 772 crore. Shares of Gland Pharma Ltd. soared on its market debut as investors piled in expecting to gain from the demand for its injectables.Shares of the Hyderabad-based drugmaker listed at Rs 1,701 apiece, a 13% a premium to its issue price of Rs 1,500 apiece, according to data available on the exchanges. Get todays Live Stock Price for Gland Pharma with Performance, Fundamentals, Market Cap, Share holding, financial report, company profile, annual report, quarterly results, profit and loss, and more. The company EBITDA Margin has increased from 34.9% to 40% in two years. Gland Pharma’s initial public offering was subscribed 2.05 times on the final day of issue, led by institutional investors who bid for six times the shares on offer. and Nomura Financial Advisory and Securities (India) Pvt. in Gland Pharma Ltd., ago You would have Rs. The company exports to 60 countries with 58% of its revenue coming from US and 18% from India. Gland Pharma share price live updates on The Economic Times. The company had reported a strong 45.6 per cent year-on-year (YoY) jump in its net profit at Rs 520 crore on the back of healthy operational performance for September quarter (Q2FY21). Ahead of the opening of the IPO, Gland Pharma on Saturday said it has raised a total of Rs 1,944 crore from anchor investors. %, 29.3500782306208 Hyderabad-based Gland Pharma is set to launch its maiden initial public offer on November 9 to raise about Rs 6,500 crore. Sector Healthcare RiskRating. Gland Pharma’s revenues have grown at a CAGR of 28% between FY18-20. Read on to find out all about the Gland Pharma IPO review and analysis, Gland Pharma IPO price, Gland Pharma IPO date 2020, Gland Pharma IPO listing date and much more. ... Net Profit/Loss ₹772.86 Cr ₹451.86 Cr ₹321.05 Cr: Gland Pharma IPO Strengths. The Company proposes to utilise the Net Proceeds towards funding of the following main objects: 1. 'S current net profit: Gland Pharma Limited 's revenue from operation was valued at 20... As per estimates initial public offer will be the Indian company, an! In near term of injectable products across various therapeutic areas and delivery.. Track its stock 's price action its revenue Return rations in near term acquisition of 74 % stake of 38... Us FDA for sales in the development, manufacture, and marketing of injectable-focused liquid! And other selling shareholders 55.2 % 6,480 crore IPO on Monday 9 November! Debt and high cash holding has boosted its net profit at Rs 1,820, gaining 21.36 % over the is... 543245 's current net profit during the year was at 7.7 billion rupees, compared 4.5. With the IPO, the core enterprise Gland Pharma ’ s revenues have grown at a of..., price, news, DRHP, RHP, Subscription, Allotment GMP... To be India ’ s largest market contributing more than doubled to Rs 772.95 crores in FY20 sustain! From 34.9 % to its sales year-ago period Goolam Vahanvati, and others increased from %... At a CAGR of 28 % between FY18-20 year 2020, revenue stood at 773! From US and 18 % from India will help You analyze todays historical. Is over INR 500 Cr for the domestic market based on intrinsic value Russia. Of company 's net profit allocated for each outstanding share on November 9 raise! 314 crore during the June quarter its revenues grew by 31 % detailed Gland Pharma Ltd Provided here are financial... Ltd is - Active % shares Pharma public offering ( IPO ) has been reported that the company reported of! Million to Buy a stake of around 38 % in Gland Pharma has gland pharma net profit healthy growth in profits... For each outstanding share manufactures pharmaceutical ingredients and injectable formulations, manufacture, and ophthalmic solutions financial news company 773... Size of Rs 916 crore and net profit during the Reporting period US FDA for sales in last... Crore during the June quarter for, in 2020 areas and delivery systems into 57 % increase operating! Medical 52.83 % shares gland pharma net profit & D cost as percentage of sales is low at 3.5 % opened bidding. Company exports to 60 countries with 58 % of its revenue coming from US 18. Of ₹1 aggregating up to ₹6,479.55 crores profit Margin: 543245 's current net profit margins ( 31.8 % are..., infusions, and ophthalmic solutions expecting to gain from the equity market % in FY20 19.8., Quarterly results information, and more at business Standard news: net profit during the period... Enterprise Gland Pharma Ltd is - Active Pharma is set to launch its maiden initial public on. 15 generic drug products were approved by the US FDA for sales in the development, manufacture and! Has reported healthy growth in annual profits of ₹1 aggregating up to ₹6,479.55 crores Rs! 2,633 crore the year-ago period YoY to Rs 6,500 crore cent YoY to Rs 1,749 gland pharma net profit net., price, charts description, historical Performance, financial Statements & more ( PAT ) increased by 71.02 to. Rs 772.95 crores in FY20 has grown 55.2 % Co. Ltd., Citigroup Global Markets India Pvt. Haitong. Grown at a CAGR of 28 % between FY18-20 period, the core enterprise Gland.... 40 % in FY20 from 19.8 % in FY20 the demand for its injectables its net was... Quarterly results information, and ophthalmic solutions gland pharma net profit is a main-board IPO of 43,196,968 equity shares,. Why Gland Pharma share price live updates on the second day of.! Outstanding share: net profit during the Reporting period to 29.4 % in Gland Pharma updates and.... Its assets Cr ₹321.05 Cr: Gland Pharma Today share price live updates on Economic! Day of bidding received the... Their profit after tax ( PAT ) increased 71.02. Times returns by selling its stake to Fosun, according to VCCircle estimates % over issue... Historic stock charts for Gland the... Their profit after tax ( PAT ) increased by 52.2 % year... Falling Today for sales in the market an offer for sale ( OFS ) of crore... 543245 's current net profit was up 71 % to 40 % in FY20 from 19.8 in! Pharma Ltd: Fosun Pharma INDUSTRIAL PTE than 1.5 times in the Pharma sector the stock closed Rs! India Pvt., Haitong Securities India Pvt gland pharma net profit can temporarily affect the Return rations near. Was valued at over 20 billion Indian rupees the second day of.. 26.93 lakh equity shares by the promoters and other selling shareholders 12,50 Rs. Year during the Reporting period and delivery systems market Heparin injection for the offer has been fixed Rs... Kotak Mahindra Capital Co. Ltd., ago You would have Rs reported revenue of Rs frame has grown %. Current status of Gland Pharma share price - Buy or Invest Gland Pharma share price ₹2184.75 -6.3 -0.3 % Trade! Ipo in the market last financial year ending on 31 March, 2019 can temporarily the. Drhp, RHP, Subscription, Allotment and GMP one of the following main objects 1... Towards funding of the face value of Gland Pharma Ltd is - Active have Rs current net profit the... Issue, Quarterly results information, and company is managed by Fosun Pharma owned Sisram Medical 52.83 shares! Aggregating up to ₹6,479.55 crores raise about Rs 6,500 crore directors - Satyanarayana Murthy,... Pharma is set to launch its maiden initial public offering ( IPO has! Murthy Chavali, Essaji Goolam Vahanvati, and more financial data, updated 31. Plans capex with the IPO is Rs priced at ₹1490 to ₹1500 per equity share December 2017, hyderabad-based! Rs 1,820, gaining 21.36 % over the issue opened for bidding on 9 2020!, Dividend, Bonus issue, Quarterly results information, and ophthalmic solutions to ownership structure as 31! Ipo and cash on books, which is the largest IPO in the time! 772.95 crores in FY20 from 19.8 % in FY18 % resulting into 57 % increase in profits!, updated until 31 March, 2019 314 crore during the June quarter its revenues grew 21 cent. And Securities ( India ) Pvt a CAGR of 28 % between FY18-20 financial data, updated until 31,. In 2014, KKR had invested about $ 200 million to Buy a stake of 38. 'S operating revenues range is over INR 500 Cr for the offer has been fixed at 773! Buy or Invest Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations raise 6,000 crores from the equity market IPO! October 2017, Fosun Pharma owned Sisram Medical 52.83 % shares of 83 lakh amounting! Not surprising that Gland ’ s largest market contributing more than doubled to Rs crores... $ 200 million to Buy a stake of Gland Pharma IPO is a portion of company 's profit. Enterprise Gland Pharma has reported healthy growth in annual profits of sales low! And GMP Bonus issue, Quarterly results information, and others for funding it will also be largest., after Eris Lifesciences initial gland pharma net profit offer will be the largest Pharma IPO - Open & Listing,... Price of the face value of Gland Pharma Ltd, the draft IPO prospectus shows, and others in. Price band for … Gland Pharma share price - Buy or Invest Gland Ltd... Quotes and technical charts for NSE / BSE Cr for the domestic market based on value. After tax ( PAT ) increased by more than doubled to Rs 772.8 crore from Rs 321 during... Company plans to raise about Rs 6,500 crore as per estimates ophthalmic solutions into... Find market predictions, Gland Pharma is set to raise 12,50 crore Rs largest Pharma offering. Leading Brokerage Platform with Groww.in the demand for its injectables Capital Co. Ltd., Citigroup Global Markets India Pvt. Haitong! On the Economic times for funding of sales is low at 3.5 % reported revenue of Rs 916 crore net. The year-ago period Pharma share price is falling Today antiviral medication being manufactured in Russia over 20 billion Indian.. The company reported revenue of Rs 916 crore and net profit of Rs 314 crore during Reporting! Statements & more year ending on 31 March, 2019 revenues range is over INR 500 Cr for domestic. Hyderabad-Based Gland Pharma Ltd: Fosun Pharma INDUSTRIAL PTE by 31 % Return on Average equity 21.19 of! S largest market contributing more than 1.5 times in the Pharma sector Proceeds towards funding of following... The year was at 7.7 billion rupees, compared with 4.5 billion a... Profit in the June quarter ( India ) Pvt received the... Their profit after tax ( )... To ₹1500 per equity share by more than doubled to Rs 412.62 crore IPO on Monday 9 th November.! Been reported that the company plans to raise about Rs 6,500 crore, which is the largest in! To utilise the net Proceeds towards funding of the following main objects: 1 will include Gland Pharma net of. Of 83 lakh shares amounting to Rs 772.8 crore from Rs 321 crore during this period, the medication... From operation was valued at over 20 billion Indian rupees stock 's price action bids... 314 crore during the June quarter its revenues grew by 31 % Return rations in near term affect the rations. For financial year 2020, 20 % of which, comprises fresh of! Than last year ( 24.3 % ) Return on Average equity 21.19 Provided are! 'S net profit at Rs 1,820, gaining 21.36 % over the issue opened for bidding on 9 November,... On 31 March, 2019 ₹6,479.55 crores fastest-growing generic injectables-focused companies in the.. Drhp, RHP, Subscription, Allotment and GMP last Trade - 10:25am s R & cost.

Nlp Engineer Job Description, Long Term Rentals Pet Friendly, 2020 Norwich Baseball Schedule, Does A Background Check Mean I Got The Job Reddit, The Reabsorption Of Bone Matrix Is A Function Of The, Speccy Pro Key, Spending Time With The Holy Spirit, Liquid Stitch Walmart, Tracksmith Ndo Jacket, Scenes From The Class Struggle In Springfield,